Skip to main content
. 2011 Nov 20;14(11):874–879. [Article in Chinese] doi: 10.3779/j.issn.1009-3419.2011.11.08

3.

多靶点药物vs单靶点药物单药治疗NSCLC疗效对比

Outcome of multi-targeted vs mono-targeted TKIs in NSCLC

Study Drug n Median PFS (week) Median OS (week) ORR (%) DCR (%)
DCR: disease control rate.
Socinski Sunitinib 63 11.3 24 9.5% 52%
Blumenschein Sorafenib 52 11.9 29 0% 59%
Ronald B Vandetanib 83 11 24 8% 45%
BR21 Erlotinib 488 9.4 28.7 6.9% 43.0%
Interest Gefitinib 659 9.4 32.6 9.7% 45.8%